Celltech, the UK-based biotech firm, has tested a new drug against rheumatoid arthritis. Thegeneti- cally engineered drugCDP 571, is based on a synthetic antibody. The antibody blocks the action of the protein that attacks the joints of rheumatoid arthritis sufferers ( The Eastern Phannacist, Vo138, No 453). When tried on 36 patients, the ~drug mitigated the pain of affected joints and slowed the disease's progression just after eight weeks' treatment.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.